-
Innovation Ranking
NewInnovation Ranking – Alfa Laval AB
Alfa Laval AB (Alfa Laval) is a provider of specialized products and solutions for heat transfer, separation, and fluid handling. Its product portfolio includes centrifuges, pumps and valves, heat exchangers, thermal fluid systems, boilers, decanters, burners, evaporation systems, high speed separators and tank equipment. The company's products optimize the processes such as heating, cooling, separating and transporting of products including oil, water, chemicals, beverages, and foodstuffs. The company caters to energy, paper and pulp, steel, chemicals, food, dairy and beverages,...
-
Innovation Ranking
NewInnovation Ranking – Alfa SAB de CV
Alfa SAB de CV (Alfa) is a diversified company that operates in the petrochemical, refrigerated food, lightweight solutions, telecommunication, and oil and gas sectors. The company develops and manufactures high-technology aluminum components for the power train and body structure of automotive. It produces processed meats, cheese, yogurt and prepared meals. Alfa provides information technologies and communications services. The company explores for hydrocarbons and produces oil and gas. Alfa serves to food, beverages, consumer products, packaging, automotive, energy markets, enterprise and...
-
Product Insights
NewNet Present Value Model: Takeda Pharmaceutical Co Ltd’s Modakafusp Alfa
Empower your strategies with our Net Present Value Model: Takeda Pharmaceutical Co Ltd's Modakafusp Alfa report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Eli Lilly and Co’s Insulin Efsitora Alfa
Empower your strategies with our Net Present Value Model: Eli Lilly and Co's Insulin Efsitora Alfa report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Denali Therapeutics Inc’s Tividenofusp alfa
Empower your strategies with our Net Present Value Model: Denali Therapeutics Inc's Tividenofusp alfa report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Chondrosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemvaleukin Alfa in Chondrosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Chondrosarcoma Drug Details: Nemvaleukin alfa (ALKS-4230) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nemvaleukin Alfa in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nemvaleukin Alfa in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nemvaleukin Alfa in Melanoma Drug Details: Nemvaleukin alfa (ALKS-4230) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Dermatomyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Dermatomyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Dermatomyositis Drug Details: Efgartigimod alfa-fcab (Vyvgart) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Efgartigimod Alfa in Polymyositis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Efgartigimod Alfa in Polymyositis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Efgartigimod Alfa in Polymyositis Drug Details: Efgartigimod alfa-fcab (Vyvgart) is a...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftilagimod Alfa in Angiosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftilagimod Alfa in Angiosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftilagimod Alfa in Angiosarcoma Drug Details: Eftilagimod alfa (IMP-321, EDP-202) is...